On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. Learn more.

On August 25, 2022, the Office of Science and Technology Policy announced a new government policy legislating the immediate public release of all United States-funded research publications by 2025. Learn more.

On June 2, 2022, at the Society for Scholarly Publishing (SSP) 44th Annual Meeting, Impact Journals, Oncotarget's publisher, received a "Certificate of Gratitude" for contributing to the SSP's Generations Fund. The Generations Fund provides long-term resources to the SSP's programs on leadership-workforce development and diversity, equity and inclusion. Learn more.

On June 25, 2022 – Impact Journals (Oncotarget's publisher) is sponsoring Team Open Access in the annual cycling event to end cancer: The Ride for Roswell. This fundraiser is hosted by Roswell Park Comprehensive Cancer Center in Buffalo, New York. Learn more.

June 1–3, 2022 – Impact Journals (Oncotarget's publisher) is a supporter and exhibitor at the Society for Scholarly Publishing (SSP) 44th Annual Meeting. We will be presenting our full scientific integrity process at the Sheraton Grand Chicago Riverwalk in Chicago, Illinois. Learn more.

On March 28, 2022 – Impact Journals publishes scholarly journals in biomedical sciences with a focus on all areas of cancer and aging research. Impact Journals is participating as an exhibitor at the American Association for Cancer Research (AACR) 2022 annual meeting from April 8-13, 2022, in New Orleans, Louisiana. This year, the AACR conference is entitled, “Decoding Cancer Complexity | Integrating Science | Transforming Patient Outcomes.”

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

On September 23, 2021, Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) launched a new web page showcasing the full Oncotarget Scientific Integrity Process.

Read about it in greater detail on Oncotarget’s new Scientific Integrity web page.

The new page also showcasts a visual representation of the number of post-publication corrections and retractions by Oncotarget compared to the industry average between 2010 and 2021. As of September 23, 2021, Oncotarget’s rate of corrections/retractions is 2.87%. The industry average correction/retraction rate is 3.80%.

Copyright © 2022 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC